deltatrials
Terminated PHASE1 INTERVENTIONAL 7-arm NCT03597282

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma

Sponsor: Apexigen America, Inc.

Conditions Metastatic Melanoma
Interventions APX005M Adjuvant NEO-PV-01 Nivolumab ipilimumab
Updated 17 times since 2018 Last updated: Sep 1, 2020 Started: Oct 8, 2018 Primary completion: May 5, 2020 Completion: Aug 11, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Closed due to historically slow enrollment compounded by the COVID-19 pandemic.

Other terminated trials from Apexigen America, Inc.

More terminations from Apexigen America, Inc.

Other Metastatic Melanoma trials with similar outcome

Browse all Metastatic Melanoma trials

This PHASE1 trial investigates Metastatic Melanoma and is currently terminated or withdrawn. Apexigen America, Inc. leads this study, which shows 17 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Sep 2019 · 4 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Aug 2020 · 7 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Jun 2023 · 29 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jun 2023 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jan 2021 — Jun 2023 [monthly]

    Terminated PHASE1

  5. Oct 2020 — Jan 2021 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

▶ Show 12 earlier versions

  1. Aug 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1

  2. Jan 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

  3. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

  5. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE1

  6. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE1

  7. May 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

  8. Mar 2019 — May 2019 [monthly]

    Recruiting PHASE1

  9. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE1

  10. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE1

  11. Nov 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  12. Aug 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Apexigen America, Inc.
  • BioNTech US Inc.
Data source: BioNTech SE

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations